The Scotland-based startup 1nhaler has raised £2.2 million in follow-on funding. The investment round was led by Archangels, with additional participation from Scottish Enterprise and BBB Investments.
The company develops a single-dose dry powder inhaler platform made primarily from cardboard. The device is designed to be the size and shape of a credit card, aiming to replace conventional plastic inhalers.
The capital will support the late-stage development of the 1nhaler Salbutamol product. Funds are allocated for technical transfer to contract manufacturing, production of clinical trial materials, and a small clinical study.
The startup plans to submit its regulatory filing by late 2027. Additionally, the company will conduct a manufacturing engineering study with Harro Höfliger to prepare for commercial scale-up.
Beyond asthma and COPD, the platform is intended for delivering other dry powder medicines, including vaccines and pain relief treatments. The team is also advancing business development discussions with potential partners.
